Categories: News

This Diwali, Xoxoday Celebrates True Indianness with India’s Own Brands

BENGALURU, India, Sept. 5, 2025 /PRNewswire/ — This Diwali, Xoxoday, a global SaaS leader in rewards and incentives, is putting the spotlight on Indigenous Indianness with the launch of its “Celebrating India” voucher. The initiative is designed to bring the joy of gifting closer to home, by championing India’s diverse homegrown brands that embody local craftsmanship, culture, and entrepreneurial spirit.

- Advertisement -

The “Celebrating India” voucher offers seamless redemption across 1000+ beloved Indian brands spanning jewelry, food, fashion, travel, wellness, and entertainment. From iconic names like Tanishq, Swiggy, Lenskart, Hotstar, Fabindia, Hidesign, Louis Philippe, to modern favorites like Nykaa, Ajio, Behrouz, and MakeMyTrip – the voucher enables consumers to celebrate Diwali with gifts that are both meaningful and authentically Indian.

- Advertisement -

Kushal Agrawal, Co-founder & CMO of Xoxoday, said:

- Advertisement -

“Diwali is about togetherness, gratitude, and celebrating the richness of our culture. With the ‘Celebrating India’ voucher, we want every Indian to gift with pride – supporting homegrown brands while spreading festive cheer. This is more than a voucher; it’s an invitation to celebrate India’s creativity, resilience, and entrepreneurial spirit. By embracing this initiative, we not only uplift individual businesses but also foster a sense of unity and strength within our diverse communities, honoring the spirit of collaboration and shared success.”

- Advertisement -

Available in flexible denominations, the vouchers can be shared digitally or as elegant physical gift cards – making them ideal for both personal and corporate gifting. Introductory festive offers of up to 15% ensure that celebrating Indian brands is both joyful and rewarding.

- Advertisement -

By choosing the “Celebrating India” voucher, consumers not only embrace gifting convenience but also become active contributors to strengthening India’s brand ecosystem – honoring local businesses and keeping Diwali celebrations truly rooted in India.

- Advertisement -

About Xoxoday

- Advertisement -

Xoxoday is a global leader in rewards, incentives, and loyalty solutions, partnering with over 5,000+ businesses worldwide. Xoxoday powers millions of users across India, Southeast Asia, the Middle East, and North America with a robust ecosystem of trusted brands and advanced engagement solutions.

- Advertisement -

Book a meeting

- Advertisement -

Media Contact
Minu Joseph
Assistant Marketing Manager, Xoxoday
Email: hello@xoxoday.com 
Website: www.xoxoday.com

- Advertisement -

Photo: https://mma.prnewswire.com/media/2764603/Celebrating_In_Xoxoday.jpg
Logo: https://mma.prnewswire.com/media/2579503/5493476/Xoxoday_Logo.jpg

- Advertisement -

 

- Advertisement -

View original content to download multimedia:https://www.prnewswire.com/in/news-releases/this-diwali-xoxoday-celebrates-true-indianness-with-indias-own-brands-302547521.html

- Advertisement -

Recent Posts

Ocular Therapeutix Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

February 06, 2026 16:01 ET  | Source: Ocular Therapeutix, Inc. BEDFORD, Mass., Feb. 06, 2026…

2 hours ago

NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

February 06, 2026 16:01 ET  | Source: NewAmsterdam Pharma N.V. NAARDEN, The Netherlands and MIAMI,…

2 hours ago

Novartis breaks ground on new global Biomedical Research center in San Diego to accelerate drug discovery

New facility will enable end‑to‑end discovery across key disease areas and technology platforms, joining existing…

2 hours ago

The Ministry of Finance and the International Monetary Fund to launch tomorrow the second edition of the AlUla Conference for Emerging Market Economies

AlUla, Saudi Arabia, Feb. 7, 2026 /PRNewswire/ -- The second edition of the AlUla Conference…

2 hours ago

Roches fenebrutinib is the first investigational medicine in over a decade that reduces disability progression in primary progressive multiple sclerosis (PPMS)

Late-breaking Phase III FENtrepid results presented at ACTRIMS show investigational fenebrutinib met its primary endpoint…

2 hours ago

Lexicon Announces Closing of Approximately $94.6 Million Public Offering and Concurrent Private Placement

February 06, 2026 17:17 ET  | Source: Lexicon Pharmaceuticals, Inc. THE WOODLANDS, Texas, Feb. 06,…

2 hours ago